Table 3 Univariate Cox regression analysis of IMWG guideline performance and SAVED scores

Individual

 Prior VTE

2.970

0.039

0.618

0.634

 Obesity

0.897

0.882

1.165

0.833

 Central venous catheter or pacemaker

0.860

0.717

1.255

0.532

 Cardiac disease (CHF, MI, CA)

0.048

0.47

1.552

0.464

 Chronic renal disease

1.717

0.224

0.693

0.541

 Diabetes

2.919

0.003

2.812

0.009

 Acute infection

0.048

0.483

0.047

0.413

 Immobilization

0.726

0.659

0.614

0.502

 Trauma or surgery

0.981

0.985

0.781

0.807

 Blood clotting disorders

NE

NE

NE

NE

 Erythropoietin

5.310

0.001

3.725

0.006

Myeloma-related

 Diagnosis of myeloma per se

N/A

N/A

N/A

N/A

 Hyperviscosity

N/A

N/A

N/A

N/A

Therapy-related

 High-dose dexamethasone, ≥ 480 mg

NE

NE

NE

NE

 Doxorubicin

2.197

0.026

2.137

0.037

 Multiagent (cytotoxic) chemotherapy

0.688

0.304

0.81

0.577

Risk stratification

 High/low

1.77

0.053

1.81

0.063

 C index

0.58

95% CI: 0.54–0.63

0.55

95% CI: 0.51–0.60

SAVED scores

Proposed risk factor

Derivation cohort

Validation cohort

HR

P value

HR

P value

Surgery (within 90 days)

0.640

0.478

0.819

0.742

Asian race

NE

NE

NE

NE

VTE history

4.378

0.008

1.108

0.920

Eighty (age ≥ 80y)

1.072

0.924

0.962

0.957

Dexamethasone dose

 Standard dose (120-160 mg)

5.404

0.002

16.737

0.006

 High dose (>160 mg)

NE

NE

NE

NE

Risk stratification

 High/low

3.225

0.248

1.647

0.622

 C index

0.51

95% CI:

0.49–0.52

0.50

95% CI:

0.49–0.51